Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05092347 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
A Phase 1 study of Chronic Kidney Disease (CKD), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 10
- Study locations
NCT05092347: Recruiting Phase 1 study of Chronic Kidney Disease (CKD), sponsored by Regeneron Pharmaceuticals.
NCT05092347 is a Phase 1 study of Chronic Kidney Disease (CKD) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 56 participants, below the 1,412-participant average among 14 other Chronic Kidney Disease (CKD) trials with a reported enrollment target (96% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05092347, a Phase 1 study of Chronic Kidney Disease (CKD), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA. The study is looking at several other research questions, including: * Side effects that may be experienced from taking vonsetamig * How vonsetamig works in the body * How much vonsetamig is present in the blood * If vonsetamig works to lower levels of antibodies to HLA
Conditions Studied
Interventions
- DRUG Vonsetamig
Study Locations (10)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California Irvine - Orange
- Connie Frank Transplant Center at UCSF - San Francisco
Connecticut
- Yale University of Medicine - New Haven
District of Columbia
- Medstar Georgetown Transplant Institute - 2-PHC - Washington D.C.
Illinois
- Comprehensive Transplant Center - Chicago
Maryland
- John Hopkins Hospital - Baltimore
Minnesota
- University of Minnesota - Minneapolis
New York
- New York University Langone Health - New York
Pennsylvania
- Penn Transplant Institute - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 1 |
What NCT05092347 shows while recruiting
NCT05092347 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,412-participant average among 14 other Chronic Kidney Disease (CKD) trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Chronic Kidney Disease (CKD) appearing as the primary indexed condition, and to 1 intervention - of which Vonsetamig is the first listed.
NCT05092347 lists 10 locations in 8 states (California, Connecticut, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT05092347 about?
NCT05092347 is a clinical study titled "A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)". The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA. The study is looking at several other...
What is the current status of trial NCT05092347?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-08-02. Estimated completion is 2027-09-01.
What conditions does trial NCT05092347 study?
This clinical trial studies the following conditions: Chronic Kidney Disease (CKD).
What interventions are being tested in trial NCT05092347?
The interventions under investigation include: Vonsetamig (DRUG).
Who is sponsoring clinical trial NCT05092347?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05092347 being conducted?
This trial has 10 study locations across California, Connecticut, District of Columbia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease (CKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05092347's enrollment target sits among peer trials
56 13th of 14 higher than 2 of 14 other Chronic Kidney Disease (CKD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease (CKD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
RECRUITING
-
Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength
RECRUITING · NA
-
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
RECRUITING
-
Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
RECRUITING
-
An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease
RECRUITING · NA
-
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI